About Olema Oncology
Olema Oncology is a company based in San Francisco (United States) founded in 2007.. Olema Oncology has raised $139 million across 4 funding rounds from investors including Lightspeed Venture Partners, Citadel and Orbimed. The company has 96 employees as of December 31, 2024. Olema Oncology offers products and services including Palazestrant and OP-3136. Olema Oncology operates in a competitive market with competitors including Daré Bioscience, Atossa Therapeutics, Puma Biotechnology, Ambagon and Minerva Biotechnologies, among others.
- Headquarter San Francisco, United States
- Employees 96 as on 31 Dec, 2024
- Stage Public
-
Sectors
Healthcare
-
Email
***********
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Olema Pharmaceuticals, Inc.
-
Annual Revenue
$00as on Dec 31, 2024
-
Net Profit
$-129.47 M-33.95as on Dec 31, 2024
-
EBITDA
$-141.87 M-35.65as on Dec 31, 2024
-
Total Equity Funding
$139 M (USD)
in 4 rounds
-
Latest Funding Round
$250 M (USD), Post-IPO
Dec 04, 2024
-
Investors
Lightspeed Venture Partners
& 18 more
-
Employee Count
96
as on Dec 31, 2024
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Olema Oncology
Olema Oncology is a publicly listed company on the NASDAQ with ticker symbol OLMA in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of Olema Oncology
Olema Oncology offers a comprehensive portfolio of products and services, including Palazestrant and OP-3136. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Monotherapy for metastatic breast cancer in clinical trials.
Inhibitor demonstrating anti-tumor activity in solid tumor models.
Unlock access to complete
Funding Insights of Olema Oncology
Olema Oncology has successfully raised a total of $139M across 4 strategic funding rounds. The most recent funding activity was a Post-IPO round of $250 million completed in December 2024. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 4
- Last Round Post-IPO — $250.0M
-
First Round
First Round
(22 Jul 2020)
- Investors Count 19
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Dec, 2024 | Amount | Post-IPO - Olema Oncology | Valuation |
investors |
|
| Sep, 2023 | Amount | Post-IPO - Olema Oncology | Valuation |
investors |
|
| Oct, 2020 | Amount | Series C - Olema Oncology | Valuation | Vivo Capital |
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Olema Oncology
Olema Oncology has secured backing from 19 investors, including venture fund and institutional investors. Prominent investors backing the company include Lightspeed Venture Partners, Citadel and Orbimed. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Investment in transformative therapeutics is managed by the firm.
|
Founded Year | Domain | Location | |
|
Venture capital investing in innovative companies across global sectors is undertaken by Lightspeed Venture Partners.
|
Founded Year | Domain | Location | |
|
Deep Track Capital is engaged in biotechnology investment activities.
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Olema Oncology
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - Olema Oncology
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Olema Oncology Comparisons
Competitors of Olema Oncology
Olema Oncology operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Daré Bioscience, Atossa Therapeutics, Puma Biotechnology, Ambagon and Minerva Biotechnologies, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Non-hormonal pharmaceutical products for female contraceptives are developed.
|
|
| domain | founded_year | HQ Location |
Drugs for breast cancer treatment and prevention are developed.
|
|
| domain | founded_year | HQ Location |
Tyrosine kinase inhibitors for breast cancer are developed.
|
|
| domain | founded_year | HQ Location |
Small-molecule therapeutics for cancer treatment are developed.
|
|
| domain | founded_year | HQ Location |
Cell therapy and antibodies are developed to treat cancer.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Olema Oncology
Frequently Asked Questions about Olema Oncology
When was Olema Oncology founded?
Olema Oncology was founded in 2007 and raised its 1st funding round 13 years after it was founded.
Where is Olema Oncology located?
Olema Oncology is headquartered in San Francisco, United States. It is registered at San Francisco, California, United States.
Is Olema Oncology a funded company?
Olema Oncology is a funded company, having raised a total of $139M across 4 funding rounds to date. The company's 1st funding round was a Series C of $85M, raised on Jul 22, 2020.
How many employees does Olema Oncology have?
As of Dec 31, 2024, the latest employee count at Olema Oncology is 96.
What does Olema Oncology do?
Olema Oncology was founded in 2007 and is headquartered in San Francisco, United States. Focus is placed on the biotechnology sector, specifically oncology, where drug therapeutics for breast cancer are developed. Operations center on clinical development, with the lead candidate OP-1250 advancing through phase 12 trials for estrogen receptor-positive, HER2-negative locally advanced or metastatic breast cancer. Research and therapeutic innovation are conducted to address unmet needs in this area.
Who are the top competitors of Olema Oncology?
Olema Oncology's top competitors include Atossa Therapeutics, Daré Bioscience and Puma Biotechnology.
What products or services does Olema Oncology offer?
Olema Oncology offers Palazestrant and OP-3136.
Is Olema Oncology publicly traded?
Yes, Olema Oncology is publicly traded on NASDAQ under the ticker symbol OLMA.
Who are Olema Oncology's investors?
Olema Oncology has 19 investors. Key investors include Lightspeed Venture Partners, Citadel, Orbimed, Janus Henderson Investors, and RA Capital.
What is Olema Oncology's ticker symbol?
The ticker symbol of Olema Oncology is OLMA on NASDAQ.